RPG Life Sciences Limited has informed the Exchange about Investor Presentation
RPGLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
RPG Life Sciences released its Annual Investor Conference presentation covering FY26 performance. The company reported record revenue of Rs 707.5 crore (up 8.3% YoY), EBITDA of Rs 172.7 crore with 24.4% margin, and EPS of Rs 69.6. ROCE improved to 28.5% and ROE to 21.1%. The Domestic Formulations business (69% of sales) outperformed the Indian Pharma Market by 1.6x, with the company rising to the 4th fastest growing company in IPM in Q4. Key brands like Naprosyn grew 16% in FY26. The company highlighted strategic priorities including building mega brands (100+ crore Naprosyn, 100+ crore Immunosuppressant portfolio), strategic acquisitions, capacity expansion, and margin optimization through cost efficiency initiatives. Cash reserves stand at Rs 276.5 crore with strong balance sheet.
Strong operational performance with market-beating growth and improving profitability signals solid execution. The company's focus on cost optimization and strategic acquisitions could drive further margin expansion, making it attractive for growth-focused investors in the pharma sector.